# US 5,700,461 A · Method for inhibiting HIV replication using IL-4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,700,461 A
- Document ID: US5700461A
- Status: Granted
- Kind: A
- Application number: 08/387,719
- Filed: 1995-02-16
- Granted: 1997-12-23
- Earliest claimed: 1992-08-19
- Assignees: Schering Corporation
- Inventors: Jerome Schwartz
- Web page: https://patentgrep.com/patent/US5700461A

## CPC

- A61K 38/2026: {IL-4}
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a method for inhibiting HIV replication in a patient which comprises administering to a patient infected with HIV a therapeutically effective amount of IL-4.

## Claims

### Claim 1

A method for inhibiting HIV replication comprising administering a therapeutically effective amount of IL-4 to a patient infected with HIV, said effective amount being sufficient to inhibit said replication.

### Claim 2 (depends on 1)

The method of claim 1 in which the IL-4 is recombinant human IL-4.

### Claim 3 (depends on 2)

The method of claim 2 wherein said effective amount of IL-4 administered is from about 0.001 .mu.g/kg to about 50 .mu.g/kg body weight per day.

### Claim 4 (depends on 3)

The method of claim 3 wherein said effective amount of IL-4 administered is from about 0.1 .mu.g/kg to about 10 .mu.g/kg body weight per day.

### Claim 5 (depends on 3)

The method of claim 3, wherein said effective amount of IL-4 administered is from about 0.05 .mu.g/kg to about 2 .mu.g/kg body weight per day.

### Claim 6 (depends on 1)

The method of claim 1 in which the route of IL-4 administration is systemic.

### Claim 7 (depends on 6)

The method of claim 6 in which the mode of systemic administration is selected from the group consisting of intravenous, intraperitoneal, intramuscular, and subcutaneous.

### Claim 8 (depends on 1)

The method of claim 1 in which the IL-4 is administered in combination with one or more other agents selected from the group consisting of AZT, ddI, and ddC.

### Claim 9

A method for inhibiting HIV replication comprising administering a therapeutically effective amount of IL-4 to a patient infected with HIV in combination with one or more other agents selected from the group consisting of AZT, ddI, and ddC.

### Claim 10 (depends on 9)

The method of claim 9 in which the IL-4 is recombinant human IL-4.

### Claim 11 (depends on 10)

The method of claim 10 wherein said effective amount of IL-4 administered is from about 0.001 .mu.g/kg to about 50 .mu.g/kg body weight per day.

### Claim 12 (depends on 11)

The method of claim 11 wherein said effective amount of IL-4 administered is from about 0.1 .mu.g/kg to about 10 .mu.g/kg body weight per day.

### Claim 13 (depends on 12)

The method of claim 12 wherein said effective amount of IL-4 administered is from about 0.05 .mu.g/kg to about 2 .mu.g/kg body weight per day.

### Claim 14 (depends on 9)

The method of claim 9 in which the route of IL-4 administered is systemic.

### Claim 15 (depends on 14)

The method of claim 14 in which the mode of systemic administration is selected from the group consisting of intravenous, intraperitoneal, intramuscular, and subcutaneous.